In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

The impact of pulmonary vascular resistance on fontan hemodynamics and outcomes

Session Poster Session 3

Speaker Alexander Egbe

Congress : ESC Congress 2018

  • Topic : valvular, myocardial, pericardial, pulmonary, congenital heart disease
  • Sub-topic : Congenital Heart Disease - Pathophysiology and Mechanisms
  • Session type : Poster Session
  • FP Number : P2600

Authors : A Egbe (Rochester,US), MA Al-Otaibi (Rochester,US), BAB Borlaug (Rochester,US)


A. Egbe1 , M.A. Al-Otaibi1 , B.A.B. Borlaug1 , 1Mayo Clinic - Rochester - United States of America ,

European Heart Journal ( 2018 ) 39 ( Supplement ), 517

Background: Central venous pressure (CVP) provides the driving force for pulmonary blood flow in Fontan physiology, and it is dependent on pulmonary vascular resistance index (PVRI), ventricular filling pressure and venous compliance. The relationship between CVP and PVRI in the Fontan physiology has not been studied. We hypothesized that in the absence of a subpulmonary ventricle in the Fontan physiology, PVRI becomes the primary determinant of CVP and Fontan related clinical outcomes.

Methods: Retrospective review of adult Fontan patients and non-congenital heart disease patients (non-CHD) that underwent cardiac catheterization at Mayo Clinic Rochester, Minnesota,1990–2015. Fontan patients were matched to the non-CHD (2:1) by age at time of catheterization (±10 years) and body mass index (±2 kg/m2).

Results: There were 164 patients and 82 patients in the Fontan and non-CHD groups respectively. In comparison to the non-CHD group, the Fontan patients were younger (median age 36 vs 45 years, p<0.001), more likely to be on anticoagulation or antiplatelet therapy, and more likely to have atrial arrhythmia or cirrhosis. There was a good correlation between CVP and PVRI in the Fontan group (r=0.79, p<0.001) in contrast to the non-CHD group where CVP was independent of PVRI. There was a weak correlation between CVP and PAWP in the Fontan group (r=0.19, p=0.04). Elevated PVRI was an risk factor for FAD (protein losing enteropathy, cirrhosis, heart failure hospitalization, arrhythmia, thromboembolism) and FAD was assisted with death (odds ratio 8.2; 95% CI 6.6–10.1, p<0.001).

Conclusions: The current study demonstrates a direct correlation between CVP and PVRI in Fontan physiology. The data suggest that elevated CVP (systemic venous congestion), which is the primary factor in the pathogenesis of most FAD and death, may to a large extent, be driven by elevation in PVR.

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

Based on your interests

Three reasons why you should become a member

Become a member now
  • 1Access your congress resources all year-round on the New ESC 365
  • 2Get a discount on your next congress registration
  • 3Continue your professional development with free access to educational tools
Become a member now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim, Bristol-Myers Squibb and Pfizer Alliance, and Novartis Pharma AG. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are